Skip to content

Author

S. P. Singh

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Polysaccharide based biomaterials for advanced wound healing applications.

Healing a wound is a complex biological process involving hemostasis, inflammation, cell proliferation, and tissue remodeling. Ad interim, polysaccharide based biomaterials have also attracted significant attention in wound healing due to their intrinsic biocompatibility, biodegradability and structural versatility, and ability to actively modulate the wound microenvironment. This review focuses on key polysaccharides, including alginate, chitosan and hyaluronic acid and discusses their roles across different stages of wound healing by correlating material structure with biological performance. The relationship between material structure and biological performance is discussed to understand their therapeutic effects. Recent advances in hybrid biomaterials, ion-coordination strategies, and stimuli-responsive dressings are highlighted for their roles in enhancing antimicrobial activity, promoting angiogenesis, and enabling controlled therapeutic delivery. Special emphasis is also placed on the emerging role of polysaccharide-based biomaterials in combating chronic wound-associated biofilms through disruption of the extracellular polymeric substance matrix, modulation of quorum-sensing pathways, and localized antimicrobial delivery. These multifunctional approaches improve infection control while simultaneously supporting tissue regeneration, thereby addressing one of the principal challenges associated with chronic wound management. The purpose of this review is to look at the impact of the use of these materials on the environment, specifically by looking at both their biodegradability and lessening of our dependency on synthetic polymers, as well as presenting an integrated design framework that links the composition, physicochemical characteristics, and biological demands of biomaterials within a time-based context to provide a rational approach for developing future wound dressings. Despite promising progress, challenges related to reproducibility, scalability, and clinical translation remain significant, underscoring the need for standardized evaluation and interdisciplinary approaches.

Pritiman Pothal, Sunny Chugh, Guramrit Kaur et al. · 0 citations
#gene editing Review Open access Sep 2026

Target, silence, replace: a review on RNA-based drugs in modern medicine

RNA therapies have evolved into a revolutionary approach in contemporary medicine for treating various diseases by directly targeting RNA molecules engaged in disease pathogenesis. These therapeutic agents regulate biological processes through diverse mechanisms, including modulation of RNA function and gene expression. Medical applications of RNA are greatly enhanced by its structure, adaptability, and capacity for targeted binding. Among these traits is its ability to bind to certain molecules unique to those chemicals. RNA-based treatments have emerged from advancements in the production, modification, and cellular transport of RNA molecules. Several RNA drugs have been approved whereas some are under trial for few diseases. RNA therapeutics can function at the level of RNAs, DNAs and proteins. The evolution of mRNA vaccines during the COVID-19 epidemic emphasizes the exciting potential of RNA therapies in the treatment of diseases. This article provides a comprehensive overview of the several forms of RNA therapies, including small-interfering RNA (siRNA), messenger RNA (mRNA), and antisense-oligonucleotides (ASOs), together with information on their action mechanisms and delivery strategies that improve cellular absorption and shield RNA molecules from degradation. Further, CRISPR-based editing of the genome can be employed for modification of target RNA sequences for various disorders. Development of RNA aptamers have also been identified as pivotal RNA-therapeutic candidate. Additionally, we have explained mechanistic details and examples of drugs approved for RNA therapy. Emphasizing their potential to enhance patient outcomes and fulfil unmet medical requirements, we also highlight the clinical development of RNA therapies in treating cancer and other infectious diseases.

Poonam Mundlia, S. P. Singh, Pritiman Pothal et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.